Clinical results analyze dexamethasone implant effect on macular thickness

Video
Conference|ARVO

Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Dr. Daniel F. Kiernan, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Recent Videos
2 experts in this video
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Related Content
A physician helps a patient undergo microperimetry imaging with the iCare MAIA. Image courtesy of iCare.

iCare announces updated MAIA TrueColor Microperimetry System

Grace Koennecke
January 20th 2025
Article

The updated device is designed to meet market diagnostic needs, including within geographic atrophy research

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A black-and-white photo of a handshake with the logos for Formycon, Klinge Biopharma and Teva over them.

Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)

Hattie Hayes
January 13th 2025
Article

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A mother who has recently given birth looks at her baby, who rests in an incubator. Image credit: ©Richard Semik – stock.adobe.com

Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics

Lynda Charters
January 10th 2025
Article

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

A gloved hand, holding a syringe, is pictured next to a US FDA (Food and Drug Administration) logo. Image credit: ©ra2 studio – stock.adobe.com

ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901

Hattie Hayes
January 9th 2025
Article

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

© 2025 MJH Life Sciences

All rights reserved.